9 Feb 2011: Molzym has today released new information about the development of the first automated platform for identification of microorganisms from blood. The system has been developed in collaboration with NorDiag. Molzym has validated the system for more than 345 microbal species, and will now launch the system which will dramatically reduce the time needed to find the right microbe. See details in attached press release.

Contact: CEO Mårten Wigstøl               Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 40 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.

For further information - www.nordiag.com.

Read the Molzym press release here

Read the notice in Norwegian here